Dullea, Robert
Pfizer (United States)
3 papers on CoChatORCID 0000-0002-7946-2034
Most cited papers
- Verified
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine
Liver Disease Diagnosis and TreatmentLipid metabolism and disorders
Cited by 219
- Verified
Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing
Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., et al. (2018) · Journal of the American Chemical Society
CRISPR and Genetic EngineeringRNA Interference and Gene Delivery
Cited by 163
- Verified
Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology
Amin, N. B., Saxena, A. R., Somayaji, V., & Dullea, R. (2023) · Clinical Therapeutics
Liver Disease Diagnosis and TreatmentLipid metabolism and biosynthesis
Cited by 48
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free